Alessia Ugolini

Milan, 20132, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs.

Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs.

Journal: Molecular therapy. Advances
Published: August 14, 2025

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

Journal: Blood
Published: July 07, 2025

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

Journal: Blood
Published: July 07, 2025

Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome.

Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome.

Journal: Frontiers in immunology
Published: May 25, 2025

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

Journal: Nature communications
Published: April 15, 2025

Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth.

Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth.

Journal: Journal of experimental & clinical cancer research : CR
Published: January 14, 2025

CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs.

CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs.

Journal: Frontiers in immunology
Published: October 17, 2024

TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.

TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.

Journal: Frontiers in immunology
Published: October 10, 2023

Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.

Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.

Journal: Nature communications
Published: September 14, 2022
Showing 1-9 of 9

Last Updated: 09/26/2026